Validation of the SSTR-RADS 1.0 for the structured interpretation of SSTR-PET/CT and treatment planning in neuroendocrine tumor (NET) patients

• DOI: 10.1007/s00330-023-09518-y
• Publication Date: 2023-03-25T07:02:54Z
• Authors: Freba Grawe; Ricarda Ebner; Thomas Geyer; Leonie Beyer; Michael Winkelmann; Gabriel T. Sheikh; Ralf Eschbach; Christine Schmid-...; Clemens C. Cyran; Jens Ricke; Peter Bartenstein; Maurice M. Heimer; Lorenzo Faggioni; Christine Spitzweg; Matthias P. Fabri...; Christoph J. Auer...; Johannes Ruebenth...
• Keywords: Radionuclide therapy; Neuroradiology; Concordance

The recently proposed standardized reporting and data system for somatostatin receptor (SSTR)-targeted PET/CT SSTR-RADS 1.0 showed promising first results in the assessment of diagnosis treatment planning with peptide radionuclide therapy (PRRT) neuroendocrine tumors (NET). This study aimed to determine intra- interreader agreement 1.0.SSTR-PET/CT scans 100 patients were independently evaluated by 4 readers different levels expertise according criteria at 2 time points within 6 weeks. For each scan, a maximum five target lesions freely chosen reader (not more than three per organ) stratified criteria. Overall scan score binary decision on PRRT assessed. Intra- was determined using intraclass correlation coefficient (ICC).Interreader identical (ICC ≥ 0.91) overall 0.93) excellent. state "functional imaging fulfills requirements qualifies patient as potential candidate PRRT" also demonstrated excellent among all 0.86). Intrareader even experience when comparing lesion-based scores 0.98), 0.93), 0.88).SSTR-RADS represents highly reproducible accurate stratifying SSTR-targeted high agreement. is approach standardize NET patients.• offers reproducibility accuracy. • method NET.